🇺🇸 FDA
Patent

US 10662160

Crystalline salts of a plasma kallikrein inhibitor

granted A61KA61K9/0019A61K9/0029

Quick answer

US patent 10662160 (Crystalline salts of a plasma kallikrein inhibitor) held by BioCryst Pharmaceuticals, Inc. expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BioCryst Pharmaceuticals, Inc.
Grant date
Tue May 26 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K9/0019, A61K9/0029, A61K9/0053, A61P